Search Results

You are looking at 1 - 1 of 1 items for :

  • Author: Thomas Tampere x
Clear All Modify Search
Stephanie Marrannes Department of Orthopedic Surgery, Ghent University, Belgium

Search for other papers by Stephanie Marrannes in
Google Scholar
PubMed
Close
,
Klaas Victor Department of Orthopedic Surgery, University of Leuven, Belgium

Search for other papers by Klaas Victor in
Google Scholar
PubMed
Close
,
Nele Arnout Department of Orthopedic Surgery, Ghent University, Belgium

Search for other papers by Nele Arnout in
Google Scholar
PubMed
Close
,
Tine De Backer Department of Cardiology, Ghent University, Belgium

Search for other papers by Tine De Backer in
Google Scholar
PubMed
Close
,
Jan Victor Department of Orthopedic Surgery, Ghent University, Belgium

Search for other papers by Jan Victor in
Google Scholar
PubMed
Close
, and
Thomas Tampere Department of Orthopedic Surgery, Ghent University, Belgium

Search for other papers by Thomas Tampere in
Google Scholar
PubMed
Close

  • Venous thromboembolism (VTE) is a well-known complication following orthopaedic surgery. The incidence of this complication has decreased substantially since the introduction of routine thromboprophylaxis. However, concerns have been raised about increased bleeding complications caused by aggressive thromboprophylaxis.

  • Attention has grown for aspirin as a safer thromboprophylactic agent following orthopaedic surgery.

  • A systematic review using MEDLINE, Embase and Web of Science databases was undertaken to compare the effectiveness of aspirin prophylaxis following knee surgery with the current standard prophylactic agents (low molecular weight heparin [LMWH], vitamin K antagonists and factor Xa inhibitors).

  • No significant difference in effectiveness of VTE prevention was found between aspirin, LMWH and warfarin. Factor Xa inhibitors were more effective, but increased bleeding complications were reported.

  • As evidence is limited and of low quality with substantial heterogeneity, further research with high-quality, adequately powered trials is needed.

Cite this article: EFORT Open Rev 2021;6:892-904. DOI: 10.1302/2058-5241.6.200120

Open access